Introduction

China's General Administration of Customs reported on February 29, 2026, that the export volume of veterinary antibiotics for livestock and poultry, including fluoroquinolones and florfenicol, grew by 18.7% year-on-year in the first quarter, reaching $230 million. The surge was primarily driven by increased demand from Southeast Asia and the Middle East, with 12 new export-approved manufacturers added during the period. This development is particularly relevant for animal health product manufacturers, agricultural exporters, and international trade compliance professionals, as it signals shifting global demand patterns and domestic production capacity adjustments.

Event Overview

According to official statistics released on February 29, 2026:

• China exported $230 million worth of veterinary antibiotics (fluoroquinolones, florfenicol, etc.) in January-February 2026
• Year-on-year growth reached 18.7%, with Southeast Asia and Middle East as primary growth markets
• 12 additional manufacturers obtained export qualifications during the period
• No policy changes or extraordinary events were cited as contributing factors

Impact on Sub-sectors

1. Veterinary API Manufacturers

The 18.7% export growth directly benefits active pharmaceutical ingredient (API) producers, particularly those with GMP-certified facilities. From an industry perspective, the new export approvals suggest regulators are accelerating compliance reviews to meet international demand.

2. Animal Health Product Formulators

Finished dosage manufacturers may face both opportunities and challenges. While export growth creates downstream demand, the entry of 12 new competitors could intensify price competition for standardized formulations.

3. Agricultural Export Trade Services

Trade intermediaries specializing in Southeast Asian and Middle Eastern markets should note the shifting product mix. Current data indicates growing preference for compliant antibiotic solutions over traditional growth promoters in these regions.

Key Focus Areas and Recommended Actions

1. Monitor Emerging Market Regulations

With Southeast Asia and Middle East driving growth, companies should track veterinary drug registration updates in Vietnam (Circular 13/2024), Indonesia (Regulation 14/2025), and Saudi Arabia (SFDA Guideline 6.3).

2. Differentiate Compliance Capabilities

The 12 new export-approved manufacturers suggest international buyers are prioritizing suppliers with auditable quality systems. Existing exporters should highlight EU GMP or WHO compliance certifications in procurement tenders.

3. Optimize Supply Chain for Volatility

Analysis shows the 18.7% growth follows two quarters of single-digit expansion. Companies should maintain flexible API procurement strategies to accommodate potential demand fluctuations.

Editorial Perspective

From an industry standpoint, this 18.7% growth appears more structural than cyclical. Three observations merit attention:

1. The simultaneous expansion of both volume and approved manufacturers suggests sustained international demand rather than one-off orders
2. Southeast Asia's shift toward regulated antibiotic use mirrors Europe's 2006 growth pattern post-antibiotic-ban
3. New entrants may accelerate industry consolidation as compliance costs favor established players

Conclusion

This export data reflects evolving global standards in livestock production rather than temporary market conditions. For industry participants, the more appropriate interpretation is that international markets are systematically transitioning toward regulated antibiotic use, creating opportunities for compliant suppliers while pressuring non-standard operators. The addition of 12 export-approved manufacturers confirms domestic capacity is responding to this structural shift.

Source Information

• Primary Source: China General Administration of Customs official release (February 29, 2026)
• Pending Verification: Whether the growth is concentrated in specific molecule categories beyond the reported fluoroquinolones and florfenicol